The Oncomine®BRCA1/2 Panel detected 21 pathogenic germline variants in 147 patients with breast and/or ovarian cancer, of which 20 were detected by the previously-launched Ion AmpliSeqTM BRCA1/2 Panel, except for one frameshift mutation. This evidence concerns the gene BRCA1 and ovarian cancer.